RxDoctor Payments Data

Johnathan Mize, MD

Internal Medicine · Hueytown, ALNPI 1679505465

Payments from drug & device makers

$14,805in general payments, 2019–2025

Across 690 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • GSK$2K
  • AstraZeneca$2K
  • AbbVie$1K
  • Pfizer$1K
  • Amgen$978
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$14,790100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,805 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$38,318
Medicare patients
149
Services billed
476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide276$301,373
TrulicityDulaglutide123$146,433
Trelegy ElliptaFluticasone/Umeclidin/Vilanter156$115,428
EliquisApixaban144$108,569
JardianceEmpagliflozin74$78,284
XareltoRivaroxaban68$65,654
FarxigaDapagliflozin Propanediol48$44,985
LinzessLinaclotide31$30,759
JanuviaSitagliptin Phosphate19$28,249
EntrestoSacubitril/Valsartan17$24,481
Xigduo XrDapaglifloz Propaned/Metformin24$20,499
MounjaroTirzepatide18$18,187
JanumetSitagliptin Phos/Metformin Hcl25$16,058
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$15,381
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$14,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,979$301,373276 claims
Lilly USA, LLCTrulicity, Mounjaro$549$164,620141 claims
GSKTrelegy Ellipta, Anoro Ellipta$2,136$130,809177 claims
PfizerEliquis$1,014$108,569144 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$832$94,694103 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,007$70,98283 claims
Johnson & JohnsonXarelto$355$65,65468 claims
MerckJanuvia, Janumet$308$44,30844 claims
AbbVieLinzess$1,046$30,75931 claims
NovartisEntresto$514$24,48117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Hueytown

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →